Xiaojie Yan

Xiaojie Yan

Auto-generated profile, based on publicly available information

Xiaojie Yan

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2021 in Science Advances
Verified
Journal Article
Open access
XYXiaojie Yan
Xiaojie Yan
QPQi Pan
Qi Pan
HXHuhu Xin
Huhu Xin
YCYuxuan Chen
Yuxuan Chen
YPYuan Ping
Yuan Ping
Targeted delivery of genome-editing prodrug by nonviral vectors promotes precision therapy of inflammatory bowel disease.

15 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
YCYuxuan Chen
Yuxuan Chen
XCXiaohong Chen
Xiaohong Chen
YZYao Zhang
Yao Zhang
MWMeng Wang
Meng Wang
MYMinqi Yang
Minqi Yang
YPYuan Ping
Yuan Ping
Macrophages play a central role in antitumor immunity, making them an attractive target for gene therapy strategies. However, macrophages are difficult to transfect because of nucleic acid sensors that can trigger the degradation of foreign plasmid DNA. Here, we developed a macrophage-specific editing (MAGE) system by which compact plasmid DNA encoding a CasRx editor can be delivered to macrophages by a poly(β-amino ester) (PBAE) carrier to bypass the DNA sensor and enable RNA editing in vitro and in vivo. We identified a four-arm branched PBAE with 1-(2-aminoethyl)-4-methylpiperazine end-capping (PBAE29) that enables highly efficient macrophage transfection. PBAE29-mediated transfection of cultured macrophages stimulated less inflammatory cytokine production and inflammasome activation compared with traditional lipofectamine or electroporation-mediated plasmid delivery. Transfection efficiency was further improved by delivering CasRx by minicircle plasmid. The MAGE system incorporated a layer of carboxylated-mannan coating to target macrophage mannose receptors and a macrophage-specific promoter for enhanced selectivity. The delivery of CasRx with guide RNA targeting the transcripts for sialic acid–binding immunoglobulin similar to lectin 10 and signal regulatory protein alpha expression resulted in effective protein knockdown, improving macrophage phagocytosis. The MAGE system also showed efficacy in targeting macrophages in vivo, stimulating antitumor immune responses and reducing tumor volume in murine tumor models, including patient-derived pancreatic adenocarcinoma xenografts in humanized mice. In sum, the MAGE system presents a promising platform for in vivo macrophage-specific delivery of RNA editing tools that can be applied as a cancer therapy.

31 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
WXWensong Xi
Wensong Xi
YXYoucui Xu
Youcui Xu
WBWeiwei Bao
Weiwei Bao
ZDZhixing Ding
Zhixing Ding
HXHu Xiao
Hu Xiao
YPYuan Ping
Yuan Ping
Sepsis, a life-threatening condition arising from a dysregulated host response to infection, remains a significant clinical challenge with limited therapeutic options. RNA editing presents a promising avenue for modulating gene expression to attenuate the inflammatory cascade characteristic of sepsis. Here, we introduce an approach utilizing chemogenetic activation of CasRx-based RNA editing via bioengineered lentiviruses for the treatment of sepsis. Our strategy involves the targeted delivery of biomineralized lentiviral vectors encoding RNA-editing enzymes and chemogenetic switches to M1 macrophage populations implicated in sepsis pathogenesis. Upon the administration of a small molecule ligand, the chemogenetic switches activate the RNA-editing tool, CasRx, thereby enabling precise and repeated downregulation of NLRP3 mRNA. We demonstrate the efficacy and repeatability of this viral-based approach in mouse models of sepsis, highlighting its potential as a versatile therapeutic strategy for mitigating sepsis-induced inflammation. This study underscores the utility of chemogenetic technologies in harnessing the power of RNA editing for the treatment of sepsis and other inflammatory disorders.

11 July 2026 in Acta Biomaterialia
Verified
Journal Article
Closed access
FZFu Zhang
Fu Zhang
CWChaorong Wang
Chaorong Wang
YHYong Huang
Yong Huang
YAYihui Ai
Yihui Ai
XYXiaojie Yan
Xiaojie Yan
YPYuan Ping
Yuan Ping